Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A compound of formula **(I)**:



(I)

wherein:

Ring A is a nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom; wherein if Ring A contains an additional nitrogen atom that nitrogen may be optionally substituted by R^7;

R^1 is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, C_{1-6}alkyl, C_{1-6}alkoxy, C_{2-6}alkenyl or C_{2-6}alkynyl;

p is 0-4; wherein the values of R^1 may be the same or different;

R^2 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, azido, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkanoyl, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, carbocyclyl-R^{34}-, heterocyclyl-R^{35}-, C_{1-6}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-6}alkoxycarbonyl, *N*-(C_{1-6}alkyl)sulphamoyl or *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl; wherein R^2 independently may be optionally substituted on carbon by one or more R^8; or R^2 is -NHR^9, -$NR^{10}R^{11}$ or -O-R^{12};

q is 0-2; wherein the values of R^2 maybe the same or different;

R^3 is halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-3}alkyl, C_{2-3}alkenyl, C_{2-3}alkynyl, C_{1-3}alkoxy, C_{1-3}alkanoyl,

N-(C_{1-3}alkyl)amino, *N,N*-(C_{1-3}alkyl)$_2$amino, C_{1-3}alkanoylamino, *N*-(C_{1-3}alkyl)carbamoyl, *N,N*-(C_{1-3}alkyl)$_2$carbamoyl, C_{1-3}alkylS(O)$_a$ wherein a is 0 to 2, *N*-(C_{1-3}alkyl)sulphamoyl or *N,N*-(C_{1-3}alkyl)$_2$sulphamoyl; wherein R^3 may be independently optionally substituted on carbon by one or more R^{13};

n is 0 to 2, wherein the values of R^3 may be the same or different;

R^4 is hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, carbocyclyl or a carbon-linked heterocyclyl; wherein R^4 may be optionally substituted on earbon by one or more R^{14}; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{15};

R^5 and **R^6** are independently selected from hydrogen, halo, nitro, eyano, hydroxy, trifluoromethoxy, amino, earboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkanoyloxy, *N*-(C_{1-6}alkyl)amino, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkanoylamino, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{1-6}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-6}alkoxycarbonyl, *N*-(C_{1-6}alkyl)sulphamoyl, *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl, C_{1-6}alkylsulphonylamino, C_{3-8}cycloalkyl or a 4-7 membered saturated heteroeyelic group; wherein R^5 and R^6 independently of each other may be optionally substituted on carbon by one or more R^{16}; and wherein if a 4-7 membered saturated heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{17};

R^7, **R^9**, **R^{10}**, **R^{11}** and **R^{12}** are independently seleeted from C_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkylsulphonyl, C_{2-6}alkenylsulphonyl, C_{2-6}alkynylsulphonyl, C_{1-6}alkoxycarbonyl, earbamoyl, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)carbamoyl, earbocyelyl, heteroeyelyl, carbocyclyl-R^{18}- or heterocyelyl-R^{19}-; wherein R^7, R^9, R^{10}, R^{11} and R^{12} may be independently optionally substituted on carbon by a group selected from R^{20}; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by R^{21};

R^{14} and **R^{20}** are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{2-6}alkenyloxy, C_{2-6}alkynyloxy, C_{1-6}alkoxyC_{1-6}alkoxy, C_{1-6}alkoxyC_{1-6}alkoxyC_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkanoyloxy, *N*-(C_{1-6}alkyl)amino, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkanoylamino, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{1-6}alkylS(O)$_a$ wherein a is 0 to 2,

C_{1-6}alkoxycarbonyl, *N*-(C_{1-6}alkyl)sulphamoyl, *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl, C_{1-6}alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC_{1-6}alkyl-R^{22}-, heterocyclylC_{1-6}alkyl-R^{23}-, carbocyclyl-R^{24}- or heterocyclyl-R^{25}-; wherein R^{14} and R^{20} may be independently optionally substituted on carbon by one or more R^{26}; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{27};

R^{18}, **R^{19}**, **R^{22}**, **R^{23}**, **R^{24}**, **R^{25}**, **R^{34}** or **R^{35}** are independently selected from -O-, -N(R^{28})-, -C(O)-, -N(R^{29})C(O)-, -C(O)N(R^{30})-, -S(O)$_s$-, -SO_2N(R^{31})- or -N(R^{32})SO_2-; wherein **R^{28}**, **R^{29}**, **R^{30}**, **R^{31}** and **R^{32}** are independently selected from hydrogen or C_{1-6}alkyl and **s** is 0-2;

R^{15}, **R^{17}**, **R^{21}** and **R^{27}** and are independently selected from C_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkylsulphonyl, C_{1-6}alkoxycarbonyl, carbamoyl, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R^{15}, R^{17}, R^{21} and R^{27} independently of each other may be optionally substituted on carbon by on or more R^{33}; and

R^{8}, **R^{13}**, **R^{16}**, **R^{26}** and **R^{33}** are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or *N*-methyl-*N*-ethylsulphamoyl;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 2 (currently amended): A compound of formula **(I)** as claimed in claim 1 wherein:

Ring A is a nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen or oxygen atom; wherein if Ring A contains an additional nitrogen atom that nitrogen may be optionally substituted by R^{7}; wherein

R^{7} is selected from C_{1-6}alkanoyl, C_{1-6}alkylsulphonyl, C_{2-6}alkenylsulphonyl, carbocyclyl-R^{18}- or heterocyclyl-R^{19}-; wherein R^{7} may be independently optionally substituted

on carbon by a group selected from R^{20}; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by R^{21};

R^{18} and R^{19} are -C(O)-;

R^{20} is selected from halo, cyano, hydroxy, C_{1-6}alkoxy, C_{2-6}alkynyloxy, C_{1-6}alkanoyloxy, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkylS(O)$_a$ wherein a is 2 or heterocyclyl; wherein R^{20} may be optionally substituted on carbon by one or more R^{26};

R^{21} is C_{1-6}alkyl; and

R^{26} is hydroxy;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 3 (currently amended): A compound of formula **(I)** as claimed in ~~either~~ claim 1 ~~or claim 2~~ wherein R^1 is halo or C_{1-6}alkyl or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 4 (currently amended): A compound ~~pf~~ of formula **(I)** as claimed in claim 1 ~~any one of claims 1-3~~wherein p is 0 or 1 or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 5 (currently amended): A compound ~~pf~~ of formula **(I)** as claimed in claim 1 ~~any one of claims 1-4~~wherein:

R^2 is selected from hydroxy, amino, azido, C_{1-6}alkyl, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, carbocyclyl-R^{34}-, -NHR^9 or -O-R^{12};

R^9 and R^{12} are independently selected from C_{1-6}alkanoyl or C_{1-6}alkylsulphonyl; wherein R^9 and R^{12} may be independently optionally substituted on carbon by a group selected from R^{20};

R^{20} is hydroxy; and

R^{34} is -N(R^{29})C(O)-; wherein R^{29} is hydrogen;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 6 (currently amended): A compound ~~pf~~ of formula **(I)** as claimed in claim 1 ~~any one of claims 1-5~~ wherein R^3 is halo or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 7 (currently amended): A compound ~~pf~~ of formula **(I)** as claimed in claim 1 ~~any one of claims 1-6~~ wherein n is 0 or 1 or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 8 (currently amended): A compound ~~pf~~ of formula **(I)** as claimed in claim 1 ~~any one of claims 1-7~~ wherein:

R^4 is C_{1-6}alkyl or carbocyclyl; wherein R^4 may be optionally substituted on carbon by one or more R^{14}; wherein

R^{14} is carbocyclyl;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 9 (currently amended): A compound of formula **(I)** as claimed in claim 1 ~~any one of claims 1-8~~ wherein:

R^5 and R^6 are independently selected from hydrogen or C_{1-6}alkyl; wherein R^5 and R^6 independently of each other may be optionally substituted on carbon by one or more R^{16}; wherein

R^{16} is selected from methoxy;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 10 (currently amended): A compound of formula **(I)**, ~~as depicted~~ as claimed in claim 1, wherein:

Ring A, R^2 and q together form piperazin-1-yl, morpholino, 4-mesylpiperazin-1-yl, 4-acetylpiperazin-1-yl, 4-(2-acetoxyacetyl)piperazin-1-yl, 4-(2-hydroxyacetyl)piperazin-1-yl, 4-(2-chloroacetyl)piperazin-1-yl, 4-(2-methoxyacetyl)piperazin-1-yl, (3-methoxypropanoyl)piperazin-1-yl, (3-hydroxy-3-methylbutanoyl)piperazin-1-yl, (3-hydroxy-2,2-dimethylpropanoyl)piperazin-1-yl,

((R)-3-methyl-2-hydroxybutanoyl)piperazin-1-yl,
((S)-3-methyl-2-hydroxybutanoyl)piperazin-1-yl,
4-(2-dimethylaminoacetyl)piperazin-1-yl, 4-[2-(dimethylamino)ethylsulphonyl]piperazin-1-yl,
4-[2-(methoxy)ethylsulphonyl]piperazin-1-yl, 4-[2-(hydroxy)ethylsulphonyl]piperazin-1-yl,
4-(cyclopropylcarbonyl)piperazin-1-yl, 4-(1-hydroxycyclopropylcarbonyl)piperazin-1-yl,
4-(1-cyanocyclopropylcarbonyl)piperazin-1-yl, 4-(2-hydroxy-2-methylpropanoyl)piperazin-1-yl,
4-((R)-2-hydroxypropanoyl)piperazin-1-yl, 4-((S)-2-hydroxypropanoyl)piperazin-1-yl,
4-((R)-2-methoxypropanoyl)piperazin-1-yl, 4-((S)-2-methoxypropanoyl)piperazin-1-yl,
4-((R)-tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl,
4-((S)-tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl, 4-(isobutyryl)piperazin-1-yl,
4-((R)-2-hydroxybutanoyl)piperazin-1-yl, 4-((S)-2- hydroxybutanoyl)piperazin-1-yl,
(R)-3-acetylaminopyrrolidin-1-yl, (S)-3-acetylaminopyrrolidin-1-yl,
(R)-2-(cyclopropylaminocarbonyl)pyrrolidin-1-yl, (R)-2-(*N*-methylcarbamoyl)pyrrolidin-1-yl,
(S)-2-(*N*,*N*-dimethylcarbamoyl)pyrrolidin-1-yl, 4-(ethenylsulphonyl)piperazin-1-yl,
4-[2-(2-propyn-1-yloxy)acetyl]piperazin-1-yl, 4-(tetrahydrofuran-3-ylcarbonyl)piperazin-1-yl,
4-(3-dimethylaminopropanoyl)piperazin-1-yl,
4-[2-(*N*-methyl-*N*-hydroxymethylamino)acetyl]piperazin-1-yl,
4-[3-hydroxy-2-(hydroxymethyl)propanoyl]piperazin-1-yl,
4-[2-(1,2,3,4-tetrazol-1-yl)acetyl]piperazin-1-yl, 4-[2-(1,2,3,4-tetrazol-5-yl)acetyl]piperazin-1-yl,
4-(1-methyl-L-prolyl)piperazin-1-yl, 4-[2-(mesyl)acetyl]piperazin-1-yl,
4-(2,2-difluoroacetyl)piperazin-1-yl, 4-[2-(pyrrolidin-1-yl)acetyl]piperazin-1-yl,
4-[2-(morpholino)acetyl]piperazin-1-yl, 4-[2-(diethylamino)acetyl]piperazin-1-yl,
4-(propionyl)piperazin-1-yl, 4-(3-hydroxypropionyl)piperazin-1-yl,
4-[2-(azetidin-1-yl)acetyl]piperazin-1-yl, (R)-3-aminopyrrolidin-1-yl,
(S)-3-aminopyrrolidin-1-yl, (3*R*,5*S*)-4-acetyl-3,5-dimethylpiperazin-1-yl,
(2*S*,5*R*)-4-acetyl-2,5-dimethylpiperazin-1-yl, (2*RS*,6*SR*)-2,6-dimethylmorpholin-4-yl]phenyl,
3-hydroxyazetidin-1-yl, 3-acetylaminoazetidin-1-yl, 3-(2-hydroxyacetylamino)azetidin-1-yl,
3-mesylaminoazetidin-1-yl, 3-mesyloxyazetidin-1-yl, 3-azidoazetidin-1-yl, 3-aminoazetidin-1-yl,
(3*R*)-3-{[(2*S*)-2-hydroxypropanoyl]amino}pyrrolidin-1-yl,
(3*S*)-3-{[(2*S*)-2-hydroxypropanoyl]amino}pyrrolidin-1-yl,

(3*S*)-3-(glycoloylamino)pyrrolidin-1-yl and (3*R*)-3-(glycoloylamino)pyrrolidin-1-yl;

R^1 is fluoro, chloro or methyl;

p is 0 or 1;

R^2 is selected from hydroxy, amino, azido, methyl, *N*-methylcarbamoyl, *N,N*-dimethylcarbamoyl, acetamido, {[(2*S*)-2-hydroxypropanoyl]amino}, glycoloylamino, mesylamino, 2-hydroxyacetamido, mesyloxy or *N*-cyclopropylcarbamoyl.

q is 0-2; wherein the values of R^2 maybe the same or different;

R^3 is 5-fluoro or 5-chloro;

n is 0 or 1;

R^4 is ethyl, isopropyl, isobutyl, cyclobutyl or cyclopropylmethyl; and

R^5 and R^6 are independently selected from hydrogen, methyl, ethyl, methoxymethyl, propyl;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 11 (currently amended): A compound of formula **(I)**, ~~as depicted~~ as claimed in claim 1, selected from:

2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-5-fluoropyrimidine hydrochloride;

2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidine;

(2*S*)-1-[4-(4-{[5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)piperazin-1-yl]-1-oxopropan-2-ol;

2-[4-(morpholino)anilino]-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-5-fluoropyrimidine

2-{4-[4-(acetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-5-fluoropyrimidine;

2-[4-(4-acetylpiperazin-1-yl)anilino]-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidine;

5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{4-[4-(methoxyacetyl)piperazin-1-yl]phenyl}pyrimidin-2-amine;

N-[4-(4-acetylpiperazin-1-yl)-3-fluorophenyl]-5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine;

N-[4-(4-acetylpiperazin-1-yl)-3-fluorophenyl]-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine; and

(2*R*)-1-[4-(4-{[5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)piperazin-1-yl]-1-oxopropan-2-ol;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 12 (currently amended): A process for preparing a compound of formula **(I)**, as claimed in claim 1 ~~any one of claims 1-11~~, or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof, which process, wherein variable groups are, unless otherwise specified, as defined claim 1, comprises of:

Process a) reaction of a pyrimidine of formula **(II)**:



(II)

wherein L is a displaceable group; with an aniline of formula **(III)**:



(III)

or

Process b) reacting a compound of formula **(IV)**:



(IV)

with a compound of formula **(V)**:



(V)

wherein T is O or S; R^x may be the same or different and is selected from C_{1-6}alkyl; or

Process c) reacting a pyrimidine of formula **(VI)**:



(VI)

wherein X is a displaceable group; with a heterocyclyl of formula **(VII)**:

(VII)

or

Process d) for compounds of formula **(I)**; reacting a pyrimidine of formula **(VIII)**



(VIII)

with a compound of formula **(IX)**:



(IX)

where Y is a displaceable group;

and thereafter ~~if necessary~~ optionally:

i) converting a compound of the formula **(I)** into another compound of the formula **(I)**;

ii) removing any protecting groups; and/or

iii) forming a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~.

Claim 13 (currently amended): A pharmaceutical composition which comprises a

compound of formula **(I)** or a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~ thereof, as claimed in ~~any one of claims 1-11~~ claim 1, in association with a pharmaceutically-acceptable diluent or carrier.

Claim 14 (currently amended): A compound of the formula **(I)**, or a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~ thereof, as claimed in ~~any one of claims 1-11~~ claim 1, for use in a method of treatment of the human or animal body by therapy.

Claim 15 (currently amended): A compound of the formula **(I)**, or a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~ thereof, as claimed in ~~any one of claims 1-11~~ claim 1, for use as a medicament.

Claims 16-20 (canceled)

Claim 21 (currently amended): A method for producing a cell cycle inhibitory, anti-cell-proliferation, effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula **(I)**, as claimed in ~~any one of claims 1-11~~ claim 1.

Claim 22 (currently amended): A method of treating cancers, solid tumours and leukaemias, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation, in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula **(I)** or a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~ thereof, as claimed in ~~any one of claims 1-11~~ claim 1.

Claim 23 (currently amended): A method of treating cancer in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an

effective amount of a compound of formula **(I)** or a pharmaceutically acceptable salt ~~or in vivo hydrolysable ester~~ thereof, as claimed in ~~any one of claims 1-11~~ claim 1.

Claim 24 (original): A method as claimed in claim 23 wherein said cancer is leukaemia, breast cancer, lung cancer, colon cancer, rectal cancer, stomach cancer, prostate cancer, bladder cancer, cancer of the pancreas, ovarian cancer, liver cancer, kidney cancer, skin cancer and cancer of the vulva.

Claim 25 (currently amended): A method of producing a CDK inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula **(I)** or a pharmaceutically acceptable salt ~~or in vivo hydrolysable ester~~ thereof, as claimed in ~~any one of claims 1-11~~ claim 1.

Claim 26 (currently amended): A pharmaceutical composition which comprises a compound of the formula **(I)**, or a pharmaceutically acceptable salt ~~*or in vivo* hydrolysable ester~~ thereof, as claimed in ~~any one of claims 1-11~~ claim 1, in association with a pharmaceutically-acceptable diluent or carrier for use in the production of a cell cycle inhibitory, anti-cell-proliferation, effect in a warm-blooded animal such as man.

Claim 27 (currently amended): A pharmaceutical composition which comprises a compound of the formula **(I)**, or a pharmaceutically acceptable salt ~~*or in vivo* hydrolysable ester~~ thereof, as claimed in ~~any one of claims 1-11~~ claim 1, in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment of cancers, solid tumours and leukaemias, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation, in a warm-blooded animal such as man.

Claim 28 (currently amended): A pharmaceutical composition which comprises a compound of the formula **(I)**, or a pharmaceutically acceptable salt ~~*or in vivo* hydrolysable ester~~

thereof, as claimed in ~~any one of claims 1-11~~ claim 1, in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment of cancer in a warm-blooded animal such as man.

Claim 29 (original): A pharmaceutical composition as claimed in claim 28 wherein said cancer is leukaemia, breast cancer, lung cancer, colon cancer, rectal cancer, stomach cancer, prostate cancer, bladder cancer, cancer of the pancreas, ovarian cancer, liver cancer, kidney cancer, skin cancer and cancer of the vulva.

Claim 30 (currently amended): A pharmaceutical composition which comprises a compound of the formula **(I)**, or a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~ thereof, as claimed in ~~any one of claims 1-11~~ claim 1, in association with a pharmaceutically-acceptable diluent or carrier for use in the production of a CDK inhibitory effect in a warm-blooded animal such as man.